Drug Profile


Alternative Names: Antibody-coupled T-cell receptor anti-CD20 immunotherapy - Unum-Therapeutics; ATTCK20; mRNA ACTR T-cells + rituximab

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unum Therapeutics
  • Developer National University Hospital (Singapore); Singapore General Hospital; Unum Therapeutics
  • Class Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Second-line therapy or greater) in Singapore (Parenteral)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in Singapore (Parenteral)
  • 03 Dec 2016 Efficacy and Adverse events data from a phase I trial in Chronic lymphocytic leukaemia (Second-line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top